胸腹主动脉瘤一期与两期杂交修复临床结局比较:综合荟萃分析
该荟萃分析纳入37项研究,比较胸腹主动脉瘤一期与两期杂交修复的临床结局。两期修复成功完成者30天死亡风险显著低于一期修复(OR 2.64,95%CI 1.36-5.12),且主要不良心脏事件和肠道并发症发生率更低。两期间动脉瘤破裂和死亡 pooled 估计分别为2%和4%。中期结局两者相当。
要点
- 两期杂交修复成功完成者30天死亡风险显著低于一期修复。
- 两期修复主要不良心脏事件和肠道并发症发生率更低。
- 两期修复期间动脉瘤破裂风险2%,死亡风险4%。
核心结论
- 对于动脉瘤破裂风险可控的患者,两期杂交修复可能更优,因其30天死亡风险、主要不良心脏事件和肠道并发症更低,且中期结局相当。
研究设计与样本
- 荟萃分析,检索Medline、Embase和Cochrane数据库(1994年1月1日至2020年5月11日),纳入报告一期和两期杂交修复结局的队列研究和病例系列,共37项研究。
主要发现
- 两期间动脉瘤破裂和死亡的 pooled 估计分别为2%(95%CI 0%-4%,I2=0%)和4%(95%CI 2%-7%,I2=0%)。
- 一期修复相比成功完成两期修复者30天死亡风险显著更高(OR 2.64,95%CI 1.36-5.12,I2=0%)。
- 主要不良心脏事件发生率:一期10%(95%CI 5%-16%),两期2%(95%CI 0%-5%)。
- 肠道并发症发生率:一期15%(95%CI 8%-25%),两期3%(95%CI 1%-6%)。
- 中期结局方面,一期和两期修复的12个月总生存率、动脉瘤相关死亡率、再干预率和移植物通畅率相当。
临床怎么用
- 对于择期胸腹主动脉瘤患者,若动脉瘤破裂风险可控,可考虑选择两期杂交修复以降低30天死亡、主要不良心脏事件和肠道并发症风险。
局限性
- 纳入研究为队列研究和病例系列,存在低至中度偏倚风险,仍需随机对照试验确认分期修复的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For thoraco-abdominal aortic aneurysms (TAAA), it is unclear whether it is better to perform hybrid repair in one (single) or two stages (staged). This study aimed to compare the clinical outcomes of single vs. staged hybrid repair of TAAA. METHODS: The Medline, Embase, and Cochrane Databases (1 January 1994 to 11 May 2020) were searched for studies on hybrid repair of TAAA. Cohort studies and case series reporting outcomes of single and staged hybrid repair of TAAA were eligible for inclusion. The Newcastle-Ottawa scale and an 18 item tool were used to assess the risk of bias. The primary outcome was 30 day mortality, and the secondary outcomes included post-operative complications, overall survival, and other mid term events. A random effects model was used to calculate pooled estimates. RESULTS: A total of 37 studies was included in the meta-analysis. The quality assessment of the included studies suggested low or moderate risk of bias. The pooled estimates for aneurysm rupture and death during stage interval were 2% (95% CI 0%-4%, I2 = 0%) and 4% (95% CI 2%-7%, I2 = 0%), respectively. Single repair was associated with a significantly higher 30 day risk of death when compared with patients who completed staged procedures successfully (OR 2.64, 95% CI 1.36-5.12, I2 = 0%). Staged repair also had lower incidence of major adverse cardiac events (MACE) (single: 10%, 95% CI 5%-16%; staged: 2%, 95% CI 0%-5%) and intestinal complications (single: 15%, 95% CI 8%-25%; staged: 3%, 95% CI 1%-6%). For mid term outcomes, single and staged repair had comparable 12 month overall survival, aneurysm related mortality, rate of re-intervention, and graft patency. CONCLUSION: Two stage hybrid repair may represent a better choice for patients with controlled risk of aneurysm rupture, because it can provide lower 30 day mortality risks, MACE, and intestinal complications, as well as comparable mid term outcomes. Randomised controlled trials are needed to ascertain the effect of repair staging in patients for elective TAAA.
引用
- Wang J, Wang T, Zhao J, et al. Comparison of Clinical Outcomes Following One versus Two Stage Hybrid Repair of Thoraco-Abdominal Aortic Aneurysms: A Comprehensive Meta-Analysis. Eur J Vasc Endovasc Surg. 2021. PMID: 33358102. doi:10.1016/j.ejvs.2020.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。